2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Adarsh Bhimraj¹, Yngve Falck-Ytter^{2

3}, Arthur Y Kim^{4

5}, Jonathan Z Li^{4

6}, Lindsey R Baden^{4

6}, Steven Johnson⁷, Robert W Shafer⁸, Shmuel Shoham⁹, Pablo Tebas¹⁰, Roger Bedimo¹¹, Vincent Chi-Chung Cheng¹², Kara W Chew¹³, Kathleen Chiotos¹⁴, Eric S Daar¹⁵, Amy L Dzierba¹⁶, David V Glidden¹⁷, Erica J Hardy¹⁸, Greg S Martin¹⁹, Christine MacBrayne²⁰, Nandita Nadig²¹, Mari M Nakamura^{22

23}, Amy Hirsch Shumaker^{2

3}, Phyllis Tien²⁴, Jennifer Loveless²⁵, Rebecca L Morgan^{2

26}, Rajesh T Gandhi^{4

5}

Affiliations

¹ Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
² Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
³ Department of Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
⁴ Harvard Medical School, Boston, Massachusetts, USA.
⁵ Infectious Diseases Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁶ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁷ Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
⁸ Department of Medicine, Stanford University, Palo Alto, California, USA.
⁹ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
¹⁰ Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹¹ Department of Medicine, UT Southwestern/VA North Texas Health Care System, Dallas, Texas, USA.
¹² Department of Microbiology, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
¹³ Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
¹⁴ Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁵ Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.
¹⁶ Department of Pharmacy, New York-Presbyterian Hospital, New York, New York, USA.
¹⁷ Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.
¹⁸ Departments of Medicine and Obstetrics and Gynecology, Brown University, Providence, Rhode Island, USA.
¹⁹ Department of Medicine, Emory University, Atlanta, Georgia, USA.
²⁰ Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado, USA.
²¹ Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
²² Antimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
²³ Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
²⁴ Department of Medicine, UCSF/VA, San Francisco, California, USA.
²⁵ Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia, USA.
²⁶ Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

PMID: 39471458
DOI: 10.1093/cid/ciae435

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Adarsh Bhimraj et al. Clin Infect Dis. 2024.

. 2024 Oct 29:ciae435.

doi: 10.1093/cid/ciae435. Online ahead of print.

Authors

Affiliations

¹ Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
² Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
³ Department of Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
⁴ Harvard Medical School, Boston, Massachusetts, USA.
⁵ Infectious Diseases Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁶ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁷ Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
⁸ Department of Medicine, Stanford University, Palo Alto, California, USA.
⁹ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
¹⁰ Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹¹ Department of Medicine, UT Southwestern/VA North Texas Health Care System, Dallas, Texas, USA.
¹² Department of Microbiology, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
¹³ Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
¹⁴ Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁵ Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.
¹⁶ Department of Pharmacy, New York-Presbyterian Hospital, New York, New York, USA.
¹⁷ Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.
¹⁸ Departments of Medicine and Obstetrics and Gynecology, Brown University, Providence, Rhode Island, USA.
¹⁹ Department of Medicine, Emory University, Atlanta, Georgia, USA.
²⁰ Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado, USA.
²¹ Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
²² Antimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
²³ Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
²⁴ Department of Medicine, UCSF/VA, San Francisco, California, USA.
²⁵ Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia, USA.
²⁶ Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

PMID: 39471458
DOI: 10.1093/cid/ciae435

Abstract

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.

Keywords: COVID-19; SARS-CoV-2; guideline; pemivibart; pre-exposure prophylaxis.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

PubMed Disclaimer

Conflict of interest statement

Possible conflicts of interest. Evaluation of relationships as potential conflicts of interest is determined by a review process. The assessment of disclosed relationships for possible COIs is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The following panelists have research-related advisor/consultant roles for indicated companies: R.B. for Shionogi, Merck, and Gilead Sciences; K.W.C. for Pardes Biosciences (concluded); E.D. for Gilead Sciences; D.V.G. for Gilead Sciences and Merck; A.K. for Shionogi; S.S. for Pfizer; P.T. for Merck and Shionogi. Importantly, these companies have developed COVID-19 treatment (but not prophylaxis) agents. No disclosures reported for all other authors including the chair and vice chair. Additional information. More detailed information on the analysis and development of recommendations is available in the Supplementary material.

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Affiliations

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Authors

Affiliations

Abstract

Conflict of interest statement

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous